Top Markets
#1 Electroneum Electroneum +19.24%
#2 Status Status +17.72%
#3 Thena Thena +12.24%
#4 Infinity Ground Infinity Ground +9.61%
#5 Ski Mask Dog Ski Mask Dog +8.58%
#6 TG.Casino TG.Casino +6.03%
#7 Bitway Bitway +4.96%
#8 City Boy City Boy +4.93%
#9 Hex Trust USD Hex Trust USD +4.55%
#10 The Grays Currency The Grays Currency +4.30%
Coin of the day
Electroneum Electroneum
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Peringkat dalam Saham #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Harga Saham
$451.59
Kapitalisasi Pasar
$114.70B
Perubahan (1 hari)
-2.36%
Perubahan (1 tahun)
-11.89%
Negara
US
Perdagangan Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

Healthcare
Laba untuk Vertex Pharmaceuticals Incorporated (VRTX)
Laba pada Dec 2025 TTM: $4.64B
Menurut laporan keuangan terbaru dari Vertex Pharmaceuticals Incorporated, laba saat ini perusahaan adalah $4.64B. Pada tahun 2024, perusahaan memperoleh laba sebesar $248.50M, penurunan dibandingkan dengan laba tahun 2023 sebesar $4.38B. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Vertex Pharmaceuticals Incorporated dari 2000 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $4.64B 0.00%
2025 $4.64B 1,768.49%
2024 $248.50M -94.33%
2023 $4.38B 3.48%
2022 $4.23B 55.01%
2021 $2.73B -12.40%
2020 $3.12B 123.45%
2019 $1.39B 132.39%
2018 $600.24M -3,925.87%
2017 $-15.69M -76.71%
2016 $-67.37M -87.96%
2015 $-559.58M -23.85%
2014 $-734.88M -24.71%
2013 $-976.12M 7,783.99%
2012 $-12.38M -120.48%
2011 $60.45M -108.01%
2010 $-754.63M 17.51%
2009 $-642.18M 38.35%
2008 $-464.18M 8.73%
2007 $-426.91M 106.35%
2006 $-206.89M 19.32%
2005 $-173.39M 9.39%
2004 $-158.51M -54.37%
2003 $-347.35M 190.28%
2002 $-119.66M 1.50%
2001 $-117.89M 119.92%
2000 $-53.61M 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B 340.58%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 12.65%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -53.96%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -65.23%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -68.75%
NL